Instituto Grifols, S.A. - otsingu tulemused

Euroopa Liit - eesti - EMA (European Medicines Agency)

flebogamma dif (previously flebogammadif)

instituto grifols s.a. - inimese normaalne immunoglobuliin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - suguhormoonid ja immunoglobuliinid, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Euroopa Liit - eesti - EMA (European Medicines Agency)

tavlesse

instituto grifols s.a. - fostamatinib dinaatrium - - trombotsütopeenia - muud süsteemse hemostatics - tavlesse on näidustatud ravi krooniliste immuunsüsteemi trombotsütopeenia (itp) täiskasvanud patsientidel, kes on tulekindlad teiste ravimitega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

veraseal

instituto grifols, s.a. - inimese fibrinogeen, inimese trombiin - hemostaas, kirurgiline - antihemorraagilised ained - toetav ravi täiskasvanutel, kui standard operatsiooni-tehnika ei piisa:et parandada haemostasisas õmblusmaterjalid toetust, kardiovaskulaarkirurgia.